Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly (NYSE: LLY) began a roll in late 2020 ... during the presidential campaign was to impose steep tariffs on products imported to the U.S. The first Trump administration also put higher ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Eli Lilly said that strong demand for these products, alongside robust performance across its oncology, immunology, and neuroscience portfolios, drove growth in the quarter. Overall, non-incretin ...

Eli Lilly (LLY) shares traded down more than 6% ... Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound — to miss consensus as well.

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...